Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020

Lessons learned from phase 1 oncology trials

A novel IO target with a chequered history is starting to look more promising - which one and why?

January 21, 2021

Strategic direction and future impacts in multiple myeloma

A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?

January 14, 2021

How bispecifics will make an impact in myeloma

Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?

January 13, 2021

Looking through the window at the cilta-cel data

A look at what we can learn from the cilta-cel BCMA CAR-T cell therapy data and where things are likely headed

January 12, 2021

An exciting pipeline of early stage oncology agents from BMS

A critical look at the early stage BMS oncology pipeline

January 11, 2021

Future of NK Cell Therapy – Part 2

Commentary on engineered NK cells, including CAR-NK and memory-like NK cells

January 6, 2021

Future of NK Cell Therapy – Part 1

Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?

January 5, 2021

If it’s Tuesday it must be Belgium

It's time to turn our attention to novel TKI approaches in hematologic malignancies

December 8, 2020

A critical review of bispecific antibodies at ASH20

What caught our attention on novel bispecific antibodies at ASH20?

December 7, 2020

ASH Day 1 highlights and lowlights Part 2

Highlights on translational research and clinical trials in AML and BCLA CAR T cell therapy

December 6, 2020

Highlights of Saturday at ASH20 Part 1

Commentary on Saturday at ASH20

December 6, 2020

Bigging up targeted therapies at ASH 2020

W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on

December 4, 2020

ASH20 Preview – Part 1 on small molecule developments

New developments in the BTK niche offer fresh insights on progress

December 1, 2020

ASH20 CAR-T cell therapy Preview

Rock around the CAR-T cell clock to learn what to watch out for at ASH20!

November 24, 2020

ASH20 Preview 2 on Antibodies and ADCs

What's hot on the antibody and ADC front at ASH 2020?

November 12, 2020

ASH20 Preview of progress with bispecific antibodies

Updated look at the bispecific landscape in early clinical development

November 9, 2020